Page 60 - The Flying Publisher Guide to Hepatitis C Treatment

60 | Hepatitis C Treatment

However, not all patients may benefit from these new types of
IFNs. In particular, it seems unlikely that patients with strong
contraindications to the current IFNs will be eligible for
treatment with newer formulations, even if the AEs profiles of
the new IFNs are milder.

Table 4.1 – New interferons in the treatment of Chronic Hepatitis C*
Interferons/ Description Clinical
Manufacturer trial phase
Interferon alfacon (consensus Bio-engineered IFN, consisting approved
interferon- INFERGEN®) of the most frequently observed
Three Rivers Pharmaceuticals amino acid in each
www.3riverspharma.com corresponding position in the
natural alfa IFN
IFN formulations with improved pharmacokinetic profiles
Albinterferon (Zalbin™) Recombinant IFN alfa-2b III
Human Genome Sciences fused with human albumin
www.hgsi.com
IFN preparations with improved side-effect profiles
Pegylated Interferon lambda Type III interferon with II
Zymogenetics/Bristol-Myers restricted receptor distribution
Squibb (especially on hepatocytes)
www.zymogenetics.com
Controlled-release recombinant interferon systems
Locteron® Recombinant IFN alfa-2b in II
BiolexTherapeutics polyetherester microspheres
www.octoplus.nl
Interferon alfa-2b XL Recombinant IFN alfa-2b with II
Flamel Technologies Medusa® nanoparticles delivery
www.flamel.com
system
II
Omega Interferon Delivered with Omega DUROS®-
Intarcia Therapeutics continuous micropump infusion
www.intarcia.com system
* According to data from: Hepatitis C new drug pipeline
(http://www.hcvdrugs.com, accessed on 4/29/2011); low dose oral interferon
(Amarillo Bioscience) and oral Belerofon (Nautilus) are not included.

Interferon alfacon or consensus interferon (CIFN) (Infergen®,
Three Rivers Pharmaceuticals) is a recombinant, bio-engineered
interferon, consisting of the most frequently observed amino
acid in each corresponding position in the natural alfa IFN. It